Signalling Pathways 2014: Programme

This symposium is designed for medical oncologists, clinical and industry researchers, and young oncologists.

Symposium objectives

C. Sessa and F. André offer a preview of the 2nd ESMO Signalling Pathways Symposium, a unique opportunity for clinicians to: get a deeper knowledge of the pathway across different diseases; learn the rationale behind targeted drugs and study pre-clinical data already available; review current indications and understand efficacy and side-effects issues.

To provide a basic introduction in the preclinical data relevant for the understanding of functional mechanisms in the PI3K/AKT/mTOR pathway
To understand basic concepts of translating preclinical observations in the PI3K/AKT/mTOR signalling into cancer clinics
To provide an essential update on different aspects important for rational clinical development of the PI3K/AKT/mTOR inhibitors
To elaborate from the clinical perspective, in a range of malignant diseases, on recent achievements and the data from currently ongoing clinical trials in targeting all axes of the PI3K/AKT/mTOR pathway

Benefits of attending

Lectures are designed to meet high-level educational standards and make an impact on personalised cancer therapy approaches
The programme is designed to accelerate the pace of translating novel and emerging cancer treatments to the bedside
Maximum interaction between audience and faculty – participation is limited to 200 attendees
The size of the event allows for increased networking opportunities
Enhanced understanding of this signaling pathway and the complexities related to its targeting in a range of tumour types from top expert faculty